Journal of Peking University(Health Sciences) >
琼 扶 , 霜 叶 . [J]. Journal of Peking University(Health Sciences), 2023 , 55(6) : 953 -957 . DOI: 10.19723/j.issn.1671-167X.2023.06.001
| 1 | Wang L , Wang FS , Gershwin ME . Human autoimmune diseases: A comprehensive update[J]. J Intern Med, 2015, 278 (4): 369- 395. |
| 2 | Arbuckle MR , McClain MT , Rubertone MV , et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003, 349 (16): 1526- 1533. |
| 3 | Furie RA , Aroca G , Cascino MD , et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2022, 81 (1): 100- 107. |
| 4 | Baker DJ , Arany Z , Baur JA , et al. CAR T therapy beyond cancer: The evolution of a living drug[J]. Nature, 2023, 619 (7971): 707- 715. |
| 5 | Maldini CR , Ellis GI , Riley JL . CAR T cells for infection, autoimmunity and allotransplantation[J]. Nat Rev Immunol, 2018, 18 (10): 605- 616. |
| 6 | Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases[J/OL]. Lancet, (2023-09-22)[2023-10-12]. https://doi.org/10.1016/S0140-6736(23)01126-1. |
| 7 | Mougiakakos D , Kr?nke G , V?lkl S , et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385 (6): 567- 569. |
| 8 | Mackensen A , Müller F , Mougiakakos D , et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28 (10): 2124- 2132. |
| 9 | Zhang W , Feng J , Cinquina A , et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR[J]. Stem Cell Rev Rep, 2021, 17 (6): 2120- 2123. |
| 10 | Qin C , Tian DS , Zhou LQ , et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results[J]. Signal Transduct Target Ther, 2023, 8 (1): 5. |
| 11 | Müller F , Boeltz S , Knitza J , et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome[J]. Lancet, 2023, 401 (10379): 815- 818. |
| 12 | Pecher AC , Hensen L , Klein R , et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome[J]. JAMA, 2023, 329 (24): 2154- 2162. |
| 13 | Bergmann C , Müller F , Distler JHW , et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells[J]. Ann Rheum Dis, 2023, 82 (8): 1117- 1120. |
| 14 | Granit V , Benatar M , Kurtoglu M , et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b/2a study[J]. Lancet Neurol, 2023, 22 (7): 578- 590. |
| 15 | Ellebrecht CT , Bhoj VG , Nace A , et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science, 2016, 353 (6295): 179- 184. |
| 16 | Sun Y , Yuan Y , Zhang B , et al. CARs: A new approach for the treatment of autoimmune diseases[J]. Sci China Life Sci, 2023, 66 (4): 711- 728. |
| 17 | Riet T , Chmielewski M . Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges[J]. Front Immunol, 2022, 13, 934343. |
/
| 〈 |
|
〉 |